Trulieve Announces Proposed Public Offering of Debenture Units
TORONTO, Oct. 29, 2019 /CNW/ – Trulieve Cannabis Corp. (“Trulieve” or the “Company”) (CSE: TRUL) today announced that it is proposing an offering (the “Offering”) under its base shelf prospectus of debenture units (the “Units”). Each Unit will be comprised of one 9.75% senior secured note maturing in 2024 (the “Notes”) and a number of subordinate voting share purchase warrants (the “Warrants”) of the Company.
Canaccord Genuity Corp. will act as the exclusive agent on a “best-efforts” basis in connection with the Offering. The Offering, if successfully completed, will be priced in the context of the market with the number of Units, issue price of the Units, number of Warrants and total size of the Offering to be determined at the time of entering into an agency agreement for the Offering.
If the Offering is successfully completed, the Company intends to use the net proceeds of the Offering for capital expenditures, acquisitions and for general corporate purposes. The Company will provide further information as events warrant.
The outstanding subordinate voting shares of the Company, the Notes and the Warrants are listed and posted for trading on the Canadian Securities Exchange (the “CSE”). The Company will apply to list the Notes and Warrants to be issued pursuant to the Offering, as well as the subordinate voting shares of the Company to be issued upon the exercise of the Warrants, on the CSE. Listing will be subject to the approval of the CSE.
A prospectus supplement to the Company’s base shelf prospectus dated May 14, 2019 (collectively, the “Prospectus”) will be filed with the securities regulatory authorities in each of the provinces of Canada, other than Quebec. The Prospectus contains important detailed information about the Offering. Copies of the base shelf prospectus and, any supplement thereto filed in connection with the Offering, can be found on SEDAR at www.sedar.com. Copies of the Prospectus may also be obtained in Canada from Canaccord Genuity Corp., 161 Bay Street, Suite 3000, Toronto, Ontario, M5J 2S1, by email at ecm@cgf.com.
About Trulieve
Trulieve is a vertically integrated “seed-to-sale” company and is the first and largest fully licensed medical cannabis company in the State of Florida. Trulieve cultivates and produces all of its products in-house and distributes those products to Trulieve-branded stores (dispensaries) throughout the State of Florida, as well as directly to patients via home delivery. Trulieve also operates in California, Massachusetts and Connecticut. Trulieve is listed on the Canadian Securities Exchange under the symbol TRUL.
This press release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or the securities laws of any state of the United States and may not be offered or sold within the “United States” or to “U.S. Persons” (as such terms are defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.
To learn more about Trulieve, visit www.Trulieve.com.
